Actively Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Led by Hoffmann-La Roche · Updated on 2026-04-24
2000
Participants Needed
28
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
CONDITIONS
Official Title
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a BMI of 30.0 kg/m2 or higher, or a BMI between 27.0 and less than 30.0 kg/m2 with at least one weight-related condition such as prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or weight-related cardiovascular disease
- History of at least one unsuccessful attempt to lose weight through diet and exercise
- Ability and willingness to self-administer the study drug or receive injections from a trained person if needed
You will not qualify if you...
- History of Type 1 or Type 2 diabetes, ketoacidosis, or hyperosmolar state/coma; prior gestational diabetes allowed if no ongoing diabetes
- Weight change greater than 5 kg within 3 months before screening
- Obesity caused by other endocrine disorders or genetic syndromes like Cushing's syndrome or Prader-Willi syndrome
- Prior or planned surgery for obesity, except liposuction or abdominoplasty performed over 1 year before screening
- Known severe gastric emptying problems
- History of acute or chronic pancreatitis or significant gallbladder disease; prior gallbladder removal allowed if done at least 3 months before screening
- Poorly controlled hypertension at screening
- Recent (within 3 months) serious cardiovascular events including heart attack, stroke, unstable angina, or heart failure hospitalization
- History of severe psychiatric disorders like unstable major depression, schizophrenia, bipolar disorder, or serious mood or anxiety disorders; stable depression or anxiety allowed if not on prohibited medications
- Treatment with any GLP-1 receptor agonist therapies within 6 months before randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 28 locations
1
Pinnacle Research Group
Anniston, Alabama, United States, 36207
Actively Recruiting
2
Arizona Clinical Trials
Tucson, Arizona, United States, 85711
Actively Recruiting
3
Artemis Institute for Clinical Research, LLC
San Diego, California, United States, 92123
Actively Recruiting
4
Elevate Clinical Research
Gurnee, Illinois, United States, 60031
Actively Recruiting
5
Monroe Biomedical Research
Louisville, Kentucky, United States, 40213
Actively Recruiting
6
International Diabetes Center At Park Nicollet
Minneapolis, Minnesota, United States, 55416
Actively Recruiting
7
Clinvest Research LLC
Springfield, Missouri, United States, 65807
Actively Recruiting
8
Headlands Reseach- Summit
Portland, Oregon, United States, 97210
Actively Recruiting
9
Trial Management Associates
Myrtle Beach, South Carolina, United States, 29572
Actively Recruiting
10
Clinical Research Associates
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
Elevate Clinical
Houston, Texas, United States, 77058
Actively Recruiting
12
Elevate Clinical
McAllen, Texas, United States, 78504
Actively Recruiting
13
CINME
Buenos Aires, Argentina, C1056ABI
Actively Recruiting
14
Paratus Clinical Western Sydney
Blacktown, New South Wales, Australia, 2148
Actively Recruiting
15
Aggarwal and Associates
Brampton, Ontario, Canada, L6T 0G1
Actively Recruiting
16
Wharton Medical Clinic
Hamilton, Ontario, Canada, L8L 5G8
Actively Recruiting
17
Kasugai Municipal Hospital
Aichi, Japan, 486-8510
Actively Recruiting
18
NTT Medical Center Sapporo
Hokkaido, Japan, 060-0061
Actively Recruiting
19
Hasegawa Medicine Clinic
Hokkaido, Japan, 066-0032
Actively Recruiting
20
Higashijujo Sakai Diabetes Internal Medicine Clinic
Tokyo, Japan, 114-0001
Actively Recruiting
21
Changhua Christian Hospital
Changhua, Taiwan, 50006
Actively Recruiting
22
Chia-Yi Christian Hospital
Chiayi City, Taiwan, 600
Actively Recruiting
23
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, 80756
Actively Recruiting
24
Chung Shan Medical University Hospital
Taichung, Taiwan, 40201
Actively Recruiting
25
China Medical University Hospital
Taichung, Taiwan, 40447
Actively Recruiting
26
National Cheng Kung University Hospital
Tainan, Taiwan, 70403
Actively Recruiting
27
National Taiwan University Hospital
Taipei, Taiwan, 10048
Actively Recruiting
28
Taipei Veterans General Hospital
Taipei, Taiwan, 112
Actively Recruiting
Research Team
R
Reference Study ID Number: WC45725 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here